[go: up one dir, main page]

AR059279A1 - Derivados de n-heteroaril-carboxamidas triciclicas que contienen un resto bencimidazol, su preparacion y su aplicacion en terapeutica - Google Patents

Derivados de n-heteroaril-carboxamidas triciclicas que contienen un resto bencimidazol, su preparacion y su aplicacion en terapeutica

Info

Publication number
AR059279A1
AR059279A1 ARP070100426A ARP070100426A AR059279A1 AR 059279 A1 AR059279 A1 AR 059279A1 AR P070100426 A ARP070100426 A AR P070100426A AR P070100426 A ARP070100426 A AR P070100426A AR 059279 A1 AR059279 A1 AR 059279A1
Authority
AR
Argentina
Prior art keywords
cycloalkyl
alkyl
aryl
alkylene
group
Prior art date
Application number
ARP070100426A
Other languages
English (en)
Inventor
David Machnik
Yannick Evanno
Luc Even
Catherine Gille
Nathalie Rakotoarisoa
Andre Malanda
Laurent Dubois
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of AR059279A1 publication Critical patent/AR059279A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pregnancy & Childbirth (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

También se refiere a un procedimiento para preparar los compuestos y su aplicacion en tratamientos terapéuticos. Reivindicacion 1: Compuesto que responde a la formula general (1) en la que: A junto con el enlace C-N del resto de bencimidazol al que está condensado, representa un heterociclo monocíclico o un heteroarilo monocíclico de 4 a 7 eslabones, que contiene de 1 a 3 heteroátomos elegidos entre O, S o N, incluido el átomo de nitrogeno del resto de bencimidazol; P representa un heterociclo bicíclico o heteroarilo bicíclico de 8, 9, 10 u 11 eslabones, que comprende de 1 a 6 heteroátomos seleccionados entre N, O y S; estando P unido al grupo -C(Y)- por un átomo de carbono; con la condicion de que cuando A represente un heterociclo saturado de 7 eslabones, P sea diferente del grupo 2,3-dihidro-1,4-benzodioxano, grupo 1-benzopiran-2-ona, grupo isoindol; R1 representa de uno a cuatro átomos o grupos, iguales o diferentes elegidos entre un átomo de hidrogeno, un átomo de halogeno, un grupo oxo, tío, alquilo C1-6, cicloalquilo C3-7, cicloalquil C3-7-alquileno C1-3, fluoroalquilo C1-6, ariloxi-alquilo C1-6, heteroariloxi-alquilo C1-6, aril-alquilenoxi C1-3-alquilo C1-6, heteroaril-alquilenoxi C1-3-alquilo C1-6, ariltio-alquilo C1-6, heteroariltio-alquilo C1-6, aril-alquilen C1-3-tio-alquilo C1-6, heteroaril-alquilen C1-3-tio-alquilo C1-6, alcoxi C1-6, cicloalquiloxi C3-7, cicloalquil C3-7-alquilenoxi C1-3, fluoroalcoxi C1-8, ciano, C(O)NR4R5, nitro, NR4R5, tioalquilo C1-6, cicloalquiltio C3-7, cicloalquil C3-7-alquilen C1-3-tio, -S(O)-alquil C1-6, -S(O)-cicloalquilo C3-7, -S(O)-alquilen C1-3-cicloalquilo C3-7, alquil C1-6-S(O)2-, fluoroalquil C1-6-S(O)2-, cicloalquil C3-7-S(O)2-, cicloalquil C3-7- alquilen C1-3-S(O)2-, SO2NR4R5, SF5, NR6C(O)R7, NR6SO2R8, R4R5NC(O)-alquileno C1-3, arilo, heteroarilo, aril- alquileno C1-5 heteroaril-alquileno C1-5, ariloxi, ariltio, heteroariloxi o heteroariltio; estando dichos grupos heteroarilo o arilo de R1 opcionalmente sustituidos con uno o varios sustituyentes R9, iguales o diferentes entre sí; con la condicion de que cuando R1 esté unido a un átomo de nitrogeno de P, entonces R1 sea diferente de un átomo de halogeno, un grupo oxo, tio, ciano, nitro, SF5, NR4R5, tioalquilo C1-6, tioarilo, tioheteroarilo, alcoxi C1-6, ariloxi, heteroariloxi, -NR6COR7 y NR6SO2R8; Y representa un átomo de oxigeno o azufre; R2 representa un átomo de hidrogeno, un átomo de halogeno, un grupo alquilo C1-6, cicloalquilo C3-7, cicloalquil C3-7-alquileno C1-3, fluoroalquilo C1-6 o alcoxi C1-6; R3 representa de 1 a 3 átomos o grupos, iguales o diferentes, elegidos entre un átomo de hidrogeno, un átomo de halogeno, un grupo alquilo C1-6, cicloalquilo C3-7, cicloalquil C3-7-alquileno C1-3, fluoroalquilo C1-6, hidroxilo, alcoxi C1-6, cicloalquiloxi C3-7, cicloalquil C3-7-alquilenoxi C1-3, cuando R3 está en un átomo de carbono; o R3 representa de 1 a 2 átomos o grupos, iguales o diferentes, elegidos entre un átomo de hidrogeno, un átomo de halogeno, grupo alquilo C1-6, cicloalquilo C3-7, cicloalquil C3-7-alquileno C1-3, fluoroalquilo C1-6, aril-C(O)-, alquil C1-6-C(O)-, cicloalquil C3-7-C(O)-, cicloalquil C3-7-alquilen C1-3-C(O)-, fluoroalquil C1-6-C(O)-, aril-S(O)2, alquil C1-6-S(O)2-, fluoroalquil C1-6-S(O)2-, cicloalquil C3-7-S(O)2, cicloalquil C3-7-alquilen C1-3-S(O)2-, alquil C1-6-O-C(O)-, aril-alquil C1-3-O-C(O)-, cicloalquil C3-7-O-C(O)-, cicloalquil C3-7-alquilen C1-3-O-C(O)-, fluoroalquil C1-6-O-C(O)-, aril-O-C(O)- , heteroaril-O-C(O)-, cuando R3 está en un átomo de nitrogeno; R4 y R5, representan, independientemente entre sí, un átomo de hidrogeno o un grupo alquilo C1-6, cicloalquilo C3-7, cicloalquil C3-7-alquileno C1- 3, aril-alquileno C1-5 o arilo; o R4 y R5 junto con el átomo de nitrogeno que los lleva, forman un grupo azetidina, pirrolidina, piperidina, azepina, morfolina, tiomorfolina, piperazina, homopiperazina, estando el grupo NR4R5 opcionalmente sustituido con un grupo alquilo C1-6, cicloalquilo C3-7, cicloalquil C3-7-alquilen C1-3, aril-alquilen C1-6, arilo, heteroarilo, aril-S(O)2-, alquil C1-6-S(O)2-, fluoroalquil C1-6-S(O)2, cicloalquil C3-7-S(O)2-, cicloalquil C3-7-alquilen C1-3-S(O)2, aril-C(O)-, alquil C1-6-C(O)-, cicloalquil C3-7-C(O)-, cicloalquil C3-7-alquilen C1-3-C(O)-, fluoroalquil C1-6-C(O)-, hidroxilo, alquiloxi C1-6, fluoroalquilo C1-6, ariloxi-alquileno C1-6, ariloxi, heteroariloxi-alquileno C1-6, heteroariloxi; R6 y R7, representan, independientemente entre sí, un átomo de hidrogeno o un grupo alquilo C1-6, cicloalquilo C3-7, cicloalquil C3-7-alquileno C1-3, aril-alquileno C1-6 o arilo; o R6 y R7juntos forman una lactama de 4 a 7 eslabones que comprende el átomo de nitrogeno y el grupo C(O) que los lleva; R8 representa un grupo alquilo C1-6, cicloalquilo C3-7, cicloalquil C3-7-alquileno C1-3, aril-alquileno C1-6 o arilo; o R6 y R8 juntos forman una sultama de 4 a 7 eslabones que comprende el átomo de nitrogeno y el grupo C(O)2 que los lleva; R9 representa un átomo de halogeno, un grupo alquilo C1-6, cicloalquilo C3-C, cicloalquil C3-7-alquilen C1-3, fluoroalquilo C1-6, alcoxi C1-6, fluoroalcoxi C1-6, nitro, ciano, NR4R5, R4R5N-alquileno C1-3, arilo, heteroarilo, ariloxi, ariltio, heteroariloxi o heteroariltio, estando dichos grupos heteroarilo o arilo opcionalmente sustituidos con uno o varios sustituyentes elegidos entre un átomo de halogeno, un grupo alquilo C1-6, cicloalquilo C3-7, cicloalquil C3-7-alquileno C1-3, fluoroalquilo C1-6, alcoxi C1-6, fluoroalcoxi C1-6, nitro, ciano, NR4R5, R4R5N-alquileno C1-3, el o los átomos de azufre del heterociclo A pueden estar en forma oxidada (S(O) o S(O)2); el o los átomos de nitrogeno pueden estar en forma oxidada (N-oxido), en el estado de base o de sal de adicion de ácido, así como en el estado de hidrato o de solvato.
ARP070100426A 2006-02-03 2007-02-01 Derivados de n-heteroaril-carboxamidas triciclicas que contienen un resto bencimidazol, su preparacion y su aplicacion en terapeutica AR059279A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0601007A FR2897061B1 (fr) 2006-02-03 2006-02-03 Derives de n-heteroaryl-carboxamides tricycliques contenant un motif benzimidazole, leur preparation et leur application en therapeutique.

Publications (1)

Publication Number Publication Date
AR059279A1 true AR059279A1 (es) 2008-03-19

Family

ID=36954977

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070100426A AR059279A1 (es) 2006-02-03 2007-02-01 Derivados de n-heteroaril-carboxamidas triciclicas que contienen un resto bencimidazol, su preparacion y su aplicacion en terapeutica

Country Status (32)

Country Link
US (2) US8143248B2 (es)
EP (1) EP1987010B1 (es)
JP (1) JP5136938B2 (es)
KR (1) KR20080090495A (es)
CN (1) CN101379041B (es)
AR (1) AR059279A1 (es)
AT (1) ATE463484T1 (es)
AU (1) AU2007211399B2 (es)
BR (1) BRPI0710480A2 (es)
CA (1) CA2637333C (es)
CY (1) CY1110168T1 (es)
DE (1) DE602007005779D1 (es)
DK (1) DK1987010T3 (es)
DO (1) DOP2007000022A (es)
EA (1) EA014450B1 (es)
ES (1) ES2344087T3 (es)
FR (1) FR2897061B1 (es)
HR (1) HRP20100327T1 (es)
IL (1) IL192648A (es)
JO (1) JO2602B1 (es)
MA (1) MA30229B1 (es)
NO (1) NO20083520L (es)
NZ (1) NZ569669A (es)
PE (1) PE20071325A1 (es)
PL (1) PL1987010T3 (es)
PT (1) PT1987010E (es)
RS (1) RS51366B (es)
SI (1) SI1987010T1 (es)
TW (1) TWI401256B (es)
UY (1) UY30130A1 (es)
WO (1) WO2007088277A1 (es)
ZA (1) ZA200806139B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2945891B2 (ja) 1998-02-16 1999-09-06 大豊建設株式会社 セグメント継手構造
FR2888848B1 (fr) * 2005-07-22 2007-09-28 Sanofi Aventis Sa Derives de n-(arylalkyl)-1h-pyrrrolopyridine-2-carboxamides, leur preparation et leur application en therapeutique
FR2911605B1 (fr) * 2007-01-19 2009-04-17 Sanofi Aventis Sa Derives de pyrrolopyridine-2-carbowamides, leur preparation et leur application en therapeutique
FR2911604B1 (fr) * 2007-01-19 2009-04-17 Sanofi Aventis Sa Derives de n-(heteroaryl-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
FR2919610B1 (fr) * 2007-08-02 2009-10-16 Sanofi Aventis Sa Derives de n-heteroaryl-carboxamides tricycliques,leur preparation et leur application en therapeutique
FR2926556B1 (fr) * 2008-01-22 2010-02-19 Sanofi Aventis Derives de carboxamides n-azabicycliques, leur preparation et leur application en therapeutique
FR2926554B1 (fr) 2008-01-22 2010-03-12 Sanofi Aventis Derives de carboxamides azabicycliques, leur preparation et leur application en therapeutique
FR2926555B1 (fr) * 2008-01-22 2010-02-19 Sanofi Aventis Derives bicycliques de carboxamides azabicycliques, leur preparation et leur application en therapeutique
FR2926553B1 (fr) * 2008-01-23 2010-02-19 Sanofi Aventis Derives d'indole-2-carboxamides et d'azaindole-2- carboxamides substitues par un groupe silanyle, leur preparation et leur application en therapeutique
WO2009108551A2 (en) * 2008-02-25 2009-09-03 H. Lundbeck A/S Heteroaryl amide analogues
US20110312938A1 (en) * 2008-06-30 2011-12-22 Ironwood Pharmaceuticals, Inc. Pyrrolopyridine Carboxylic Acid Derivatives
US20100113472A1 (en) * 2008-11-03 2010-05-06 Chemocentryx, Inc. Compounds for the treatment of osteoporosis and cancers
KR20110132564A (ko) * 2009-02-11 2011-12-08 선오비온 파마슈티컬스 인코포레이티드 히스타민 ｈ3 역 작용제 및 길항제, 및 이의 사용 방법
EP2475664A2 (en) * 2009-09-11 2012-07-18 Sunovion Pharmaceuticals Inc. Histamine h3 inverse agonists and antagonists and methods of use thereof
CN102858772A (zh) * 2010-04-27 2013-01-02 安斯泰来制药株式会社 咪唑并[1,2-a]吡啶衍生物
CN104203950B (zh) 2012-03-16 2016-08-24 生命医药公司 肝x受体调节剂
HUE029402T2 (en) 2012-03-16 2017-02-28 Vitae Pharmaceuticals Inc Liver X receptor modulators
US9499562B2 (en) 2012-06-18 2016-11-22 Dart Neuroscience (Cayman) Ltd. Substituted thiophene- and furan-fused azolopyrimidine-5-(6H)-one compounds
WO2016020288A1 (en) 2014-08-04 2016-02-11 Nuevolution A/S Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
WO2016210294A1 (en) * 2015-06-25 2016-12-29 Promega Corporation Thienopyrrole compounds and uses thereof as inhibitors of oplophorus-derived luciferases
CA3037587A1 (en) * 2016-09-30 2018-04-05 Epizyme, Inc. Substituted fused bi- or tri- heterocyclic compounds as ehmt2 inhibitors
EP3562823B1 (en) 2016-12-28 2023-02-08 Promega Corporation Functionalized nanoluc inhibitors
CN110621316B (zh) 2017-04-21 2024-01-26 Epizyme股份有限公司 用ehmt2抑制剂进行的组合疗法
CN109761974B (zh) * 2019-01-21 2021-05-14 河南大学 1,2,3,4-四氢-9H-吡啶并[3,4-b]吲哚类TRPV1拮抗剂及其应用
JOP20220160A1 (ar) 2019-12-20 2023-01-30 Nuevolution As مركبات فعّالة نحو مستقبلات نووية
EP4076657A1 (en) 2019-12-20 2022-10-26 Nuevolution A/S Compounds active towards nuclear receptors
MX2022012260A (es) 2020-03-31 2022-11-30 Nuevolution As Compuestos activos frente a receptores nucleares.
MX2022012259A (es) 2020-03-31 2022-12-08 Nuevolution As Compuestos activos frente a receptores nucleares.
CN114276354B (zh) * 2022-01-07 2023-06-02 中山大学 1-氨基苯并[4,5]咪唑并[1,2-a]吡嗪-3-甲酰胺类化合物及其制备和应用
CN114539265B (zh) * 2022-03-02 2023-07-21 中山大学 靶向a2a的苯并咪唑并吡嗪-3-甲酰胺及其肿瘤免疫功能

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003037274A2 (en) * 2001-11-01 2003-05-08 Icagen, Inc. Pyrazole-amides and-sulfonamides
WO2004007495A1 (ja) * 2002-07-11 2004-01-22 Takeda Pharmaceutical Company Limited ピロロピリジン誘導体およびその用途
EP2308848A1 (en) * 2003-02-03 2011-04-13 Janssen Pharmaceutica NV Quinoline-derived amide modulators of vanilloid VR1 receptor
GB0322016D0 (en) * 2003-09-19 2003-10-22 Merck Sharp & Dohme New compounds
US7544803B2 (en) * 2004-01-23 2009-06-09 Amgen Inc. Vanilloid receptor ligands and their use in treatments
DE102004021716A1 (de) * 2004-04-30 2005-12-01 Grünenthal GmbH Substituierte Imidazo[1,2-a]pyridin-Verbindungen und Arzneimittel enthaltend substituierte Imidazo[1,2-a]pyridin-Verbindungen
JP4018739B2 (ja) * 2004-07-15 2007-12-05 日本たばこ産業株式会社 縮合ベンズアミド化合物及びバニロイド受容体１型（ｖｒ１）活性阻害剤

Also Published As

Publication number Publication date
CY1110168T1 (el) 2015-01-14
CN101379041A (zh) 2009-03-04
US20090042873A1 (en) 2009-02-12
TW200738726A (en) 2007-10-16
IL192648A0 (en) 2009-02-11
CN101379041B (zh) 2012-08-29
EP1987010B1 (fr) 2010-04-07
AU2007211399A1 (en) 2007-08-09
WO2007088277A1 (fr) 2007-08-09
UY30130A1 (es) 2007-09-28
EA200870226A1 (ru) 2009-02-27
DOP2007000022A (es) 2007-09-15
HRP20100327T1 (hr) 2010-08-31
CA2637333C (fr) 2015-12-29
DE602007005779D1 (de) 2010-05-20
AU2007211399B2 (en) 2012-09-20
ZA200806139B (en) 2010-05-26
ATE463484T1 (de) 2010-04-15
KR20080090495A (ko) 2008-10-08
PT1987010E (pt) 2010-06-25
IL192648A (en) 2012-06-28
NZ569669A (en) 2011-05-27
JP2009525313A (ja) 2009-07-09
CA2637333A1 (fr) 2007-08-09
EA014450B1 (ru) 2010-12-30
TWI401256B (zh) 2013-07-11
US8288376B2 (en) 2012-10-16
BRPI0710480A2 (pt) 2012-08-14
JO2602B1 (en) 2011-11-01
US8143248B2 (en) 2012-03-27
PL1987010T3 (pl) 2010-09-30
JP5136938B2 (ja) 2013-02-06
HK1129670A1 (en) 2009-12-04
PE20071325A1 (es) 2008-02-21
EP1987010A1 (fr) 2008-11-05
MA30229B1 (fr) 2009-02-02
FR2897061A1 (fr) 2007-08-10
RS51366B (sr) 2011-02-28
US20120122852A1 (en) 2012-05-17
DK1987010T3 (da) 2010-08-02
NO20083520L (no) 2008-09-11
SI1987010T1 (sl) 2010-07-30
ES2344087T3 (es) 2010-08-17
FR2897061B1 (fr) 2010-09-03

Similar Documents

Publication Publication Date Title
AR059279A1 (es) Derivados de n-heteroaril-carboxamidas triciclicas que contienen un resto bencimidazol, su preparacion y su aplicacion en terapeutica
AR070207A1 (es) Derivados biciclicos de carboxamidas aza- biciclicas su preparacion y su aplicacion terapeutica
AR044874A1 (es) Derivados de 4- cianopirazol-3 - carboxamida, su preparacion y su aplicacion en terapeutica
AR070208A1 (es) Derivados de carboxamidas n- azabiciclicas su preparacion y su aplicacion en terapeutica
AR061651A1 (es) Analogos de piridina ii
AR070206A1 (es) Derivados de carboxamidas azabiciclicas su preparacion y su aplicacion en terapeutica
CO6300864A2 (es) Derivados polisustituidos de 6-heteroaril-imidazo[1,2-a]piridinas su preparacion y su aplicacion en terapeutica
AR076562A1 (es) Derivados de ciclopenta (c) pirrol-2- carboxilatos, su preparacion y su aplicacion en terapeutica
AR057107A2 (es) Uso de compuestos derivados de piperazina utiles como antagonistas ccr5, para la preparacion de medicamentos
PE20080524A1 (es) DERIVADOS DE 1H-IMIDAZO[4,5-b]PIRAZIN Y COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN
AR070994A1 (es) Derivados polisustituidos de 2-heteroaril-6-fenil-imidazo[1,2-a]piridina, composiciones farmaceuticas que los contienen, proceso de preparacion de los mismos, intermediarios de sintesis y uso de los mismos en el tratamiento o prevencion de enfermedades que implican receptores nucleares nurr-1, tales
AR076563A1 (es) Derivados de ciclopenta[c]pirrol-2-carboxilatos, su preparacion y su apli-cacion en terapeutica
AR078168A1 (es) Derivados de piperidinas y piperazinas, procesos para prepararlos y sus usos como moduladores de gpr119
AR068503A1 (es) Derivados de amidas sustituidas, composicion farmaceutica y usos.
AR086143A1 (es) Derivados de imidazopiridina como inhibidores de pi3k
AR058073A1 (es) Derivados de imidazol 5-il-pirimidina, procesos de obtencion, composiciones farmaceuticas y usos
PE20020468A1 (es) Compuestos macrolidos como agentes antibacterianos y antiprotozoarios
AR063393A1 (es) Derivados de benzoil amino heterociclilos utiles en el tratamiento de enfermedades originadas por la glk
AR069480A1 (es) Derivados de 2-amino-pirimidina
AR070648A1 (es) Derivados de bencimidazol sustituido
AR069813A1 (es) Derivados de 2- amino-pirimidina, una composicion farmaceutica, un metodo de preparacion del compuesto y uso del mismo para preparar un medicamento
ES2476422T3 (es) Compuestos de piperidina 3,5-sustituida como inhibidores de renina
PE20050231A1 (es) Derivados de piperidinium y pirrolidinium como antagonistas del receptor muscarinico m3
CO5690593A2 (es) Nuevos derivados de pirimidin 2-amina
AR055554A1 (es) Compuestos piridinicos, composicion farmaceutica y uso de los compuestos para preparar medicamentos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal